Fungal Keratitis Treatment Market Size, Share & Trends Analysis Report By Keratitis Type (Noninfectious Keratitis, Infectious Keratitis), By Drug Class (Polyenes, Azoles, Fluorinated Pyrimidines), By Route of Administration (Oral, Injections, Topical Antifungals), By Age Group (0-18 Years, 18-39 Years, 40-64 Years, 65 Years), By Distribution Channel (Hospitals, Drug stores, Others) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2026-2034

Fungal Keratitis Treatment Market Size

The global fungal keratitis treatment market size was valued at USD 0.95 billion in 2025 and is projected to grow from USD 0.99 billion in 2026 to USD 1.44 billion by 2034, registering a CAGR of 4.71% during the forecast period from 2026 to 2034. North America dominated the fungal keratitis treatment market with a market share of 38.5% in 2025.

The fungal keratitis treatment market is driven by rising cases of fungal keratitis worldwide, the increasing awareness of the potential dangers posed by fungal keratitis, and the advancements in its therapeutics. It is estimated that the incidence of fungal keratitis would exceed one million cases per year, with 8 to 11 percent of patients losing an eye. Fungal keratitis is an increasingly prevalent infection and for which the Aspergillus species are the most common causal agent for fungal keratitis.

Trauma, contact lens use, topical corticosteroid use, diabetes mellitus, and low socioeconomic status are risk factors for fungal keratitis. Undoubtedly, accidental ocular trauma is the most prevalent risk factor for fungal keratitis. The estimated prevalence rate of fungal keratitis is based on an infection of the cornea, which is frequently caused by improper care and cleaning of contact lenses or corneal injury. Increasing research activities to develop novel therapeutics and rising sales volume of ophthalmic drugs for fungal keratitis disorders are anticipated to be one of the major market drivers during the forecast period.

Government initiatives, such as awareness campaigns may also contribute to the growth of the fungal keratitis treatment market. In one of India's states, for example, the Government of Assam operates a "National Programme for Control of Blindness" to reduce the prevalence of blindness and its underlying diseases, such as fungal keratitis. It can aid in taking the necessary preventative measures. The provision of better health care facilities and the dissemination of information regarding the benefits of better and earlier diagnoses could serve as a motivating factor.

Drug Class Insights

Based on the drug class, the market is segmented into Polyenes, Azoles, and Fluorinated Pyrimidines. Polyenes such as amphotericin B are often used for severe fungal keratitis, particularly caused by Candida species. Azoles such as voriconazole and ketoconazole are typically used for fungal keratitis, and voriconazole, in particular, has shown efficacy against a wide range of fungal pathogens. Fluorinated Pyrimidines are another class of antifungal drugs and are less common compared to the other two drug classes.

With respect to the route of administration, it is further segmented as an oral, injection, and topical. The topical segmentation is the most dominant one, with a market share of USD 199.4 million in 2023 and expected to reach USD 310.69 million by 2032 at a CAGR of 5.7%. Topical antifungals, either commercially available or compounded from a systemic preparation into eye drops, are the most frequently prescribed medications for the treatment of fungal keratitis.

The only topical antifungal medication approved for the treatment of fungal keratitis is natamycin. However, inadequate ocular penetration is the primary market constraint. On the other hand, due to the approval of new topical formulations for fungal keratitis, the topical route of administration is anticipated to experience substantial growth over the forecast period.

The oral route of administration is the second most utilized one, which has a market value of USD 167.6 million in 2023 and reaching at USD 259.17 million by 2032 at a CAGR of 5.6%. Oral treatment is conventional and the most reliable route of drug administration, with effective systemic and local effects. In addition, both the physician and the patient favor this route of drug administration.

Request Customizationto receive a tailored report.

Distribution Channel Insights

The distribution channel, the said market is segmented into hospitals and drug stores,and others, wherethe hospital segment accounted for the largest market share of USD 294 million in 2023 and is forecasted to reach USD 441.04 million by 2032, at a CAGR of 5.2%.

Drug store is anticipated to hold second largest market share of USD 211.34 million in 2023 and is estimated to grow to USD 314.63 million by 2032, at a CAGR of 5.1%. Independent pharmacies with a state license to dispense medications to the general public at retail prices are referred to as drug stores.

Speak to an Analystto discuss market opportunities.

Regional Insights

North America region is the largest market for fungal keratitis treatment, with a market size of USD 299.02 million in 2023 and a projected market size of USD 317.04 million by 2032, at a CAGR of 5.2%. The market growth in this region is driven by the high prevalence of fungal keratitis, the increasing awareness of the disease, the availability of advanced diagnostic and therapeutic options, and the presence of key players in the market.

Unlock Regional Insightsto access country-level data, & regional trends.

Europe Market Trends

Europe is the second largest market for fungal keratitis treatment, with a market size of USD 201.01 million in 2023 and an expected market size of USD 315.56 million by 2032, at a CAGR of 5.8%. The market growth in this region is influenced by the rising incidence of fungal keratitis, the growing demand for effective and affordable antifungal drugs, and the increasing research and development activities in the field.

Asia-Pacific: Fastest Growing Market

Asia-Pacific is the fastest growing market for fungal keratitis treatment, with a market size of USD 258.09 million in 2023 and an anticipated market size of USD 408.26 million by 2032, at a CAGR of 5.9%. The market growth in this region is fueled by the large population base, the high rate of ocular trauma, the low socioeconomic status, and the improving healthcare infrastructure and access.

List of Key and Emerging Players in Fungal Keratitis Treatment Market